Hepatocellular carcinoma recurrence rates and patterns did not differ between patients who underwent interferon-based antiviral therapy for hepatitis C and those who received direct-acting antiviral ...

According to data from eight studies being presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, there remains continued debate on whether patients are at risk of ...

Please provide your email address to receive an email when new articles are posted on . “The majority of recent publications reveal no increased risk of liver cancer in patients treated with DAAs — ...

A study published in 2016 raised concerns that patients with liver cancer related to hepatitis C virus (HCV) may have a higher risk for recurrence if they are treated with direct-acting antiviral (DAA ...

Credit: Shutterstock. Direct-acting antiviral therapy is not associated with increased overall or early hepatocellular carcinoma recurrence among patients with a previous complete response to HCC ...